According to a study published by Insure Insights, the global therapeutic protein market is estimated to grow at a CAGR of 9.6% during the forecast period. Therapeutic proteins are the developed proteins in the laboratory intended for pharmaceutical use. Recombinant DNA technology makes it easy to make proteins in particular host cells such as bacteria, yeast, or mammalian cells under optimum conditions. The host for production chosen depends on the protein required. Mammalian cells are the most favored host cell as their posttranslational modifications like glycosylation and sialylation significantly impact the protein’s pharmacokinetics and protein’s efficiency. Therapeutic proteins help in the personalized medicine concept. They make it easy for the individualized treatment by associating with the specifically targeted therapeutic procedure by recompensing the deficiency of the deficient protein.

Top Driver: Introduction & Adoption of New Plasma-Derived Therapies and Rising in the Prevalence of Chronic Disorders

The major factors that propel the growth of the global protein therapeutics market are the introduction & adoption of new plasma-derived therapies, rising in the prevalence of chronic & life-threatening diseases, and growing awareness among the populace concerning the high efficiency of protein therapeutics. On the other hand, the high cost of protein therapies and complex reimbursement scenarios hinder market growth. Conversely, introduction in novel indications for known protein therapeutics and untapped emerging markets are expected to create lucrative opportunities for the manufacturers in this industry.

Cancer Segment is Estimated to Witness Significant Growth During the Forecast Period

The global therapeutic protein market has been segmented into cancer, infectious disease, hemophilia, and others on the basis of indications. Among these, cancer segment is estimated to holds the largest market share and is expected to continue the trend during the forecast period. The growth is attributed to increasing incidences of cancer across the world. On the basis of therapeutic protein type, the market is segmented into monoclonal antibodies, erythropoietin, insulin, interferon, and others. On the end-user, the market is segmented into pharmaceutical companies, healthcare service providers, research organizations, and others.

   Emerging Market Players in the Untapped Region and Rising R&D Activities to Benefit Asia Pacific Market

Asia-Pacific is expected to be the fastest-growing regional market. The growth is attributed to the emerging market players in the untapped region, rising R&D activities in the protein therapeutics segment, growing focus of government toward vaccination to prevent various diseases, and massive target population. For instance, the Japanese government has been offering free hepatitis testing since 2002 for all citizens aged between 40 and 70 years of age as part of routine health check-up. The rising geriatric population is one of the significant factors propelling market growth in the region.

Players to Focus on Research and Development

The global therapeutic market is estimated to stay fragmented during the forecast period owing to the possible new entrants. The major market players operating in the market include Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi. Other players (profiles not included in the report) in the value chain analysis include Biogen, Inc., CSL Behring, and Genentech, Inc.

Baxter International Inc.: In September 2020, Baxter International Inc., a global leader in clinical nutrition received the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix Injections and Clinimix E Injections. The Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S., making it easier to reach patient protein targets while delivering less fluid and dextrose than provided by existing formulations.

Scope of the Report

By Indication

• Cancer
• Hemophilia
• Infectious disease
• Others

By Therapeutic Protein  

• Monoclonal Antibodies
• Interferon
• Erythropoietin
• Insulin
• Others

By End-Users  

• Pharmaceutical companies
• Healthcare service providers
• Research Organizations
• Academic Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.